Doxofylline as a steroid-sparing treatment in Mexican children with asthma.
| Autor: | González-Díaz SN; Regional Center of Allergy and Clinical Immunology, University Hospital 'Dr Jose Eleuterio Gonzalez', Autonomous University of Nuevo León, Monterrey, Mexico., Ansotegui IJ; Department of Allergy and Immunology, Hospital Quironsalud Bizkaia, Erandio-Bilbao, Spain., Macouzet-Sánchez C; Regional Center of Allergy and Clinical Immunology, University Hospital 'Dr Jose Eleuterio Gonzalez', Autonomous University of Nuevo León, Monterrey, Mexico., Acuña-Ortega N; Regional Center of Allergy and Clinical Immunology, University Hospital 'Dr Jose Eleuterio Gonzalez', Autonomous University of Nuevo León, Monterrey, Mexico., de la Cruz-de la Cruz C; Regional Center of Allergy and Clinical Immunology, University Hospital 'Dr Jose Eleuterio Gonzalez', Autonomous University of Nuevo León, Monterrey, Mexico. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | The Journal of asthma : official journal of the Association for the Care of Asthma [J Asthma] 2024 Jun; Vol. 61 (6), pp. 574-583. Date of Electronic Publication: 2023 Dec 28. |
| DOI: | 10.1080/02770903.2023.2294909 |
| Abstrakt: | Objective: The aim of this pilot study was to assess the efficacy of doxofylline as an ICS-sparing agent in the treatment of Mexican children with asthma. Methods: 10-week, open-label, crossover, pilot study, we examined the steroid-sparing effect of doxofylline in Mexican children with asthma. Patients aged 6-16 years treated with inhaled corticosteroids (ICS) for at least 8 wk before enrollment were divided randomly into two groups at the baseline visit. Group A ( n = 31) received doxofylline (18 mg/kg/day) plus standard-dose budesonide (D + SDB) for the first 4-week period followed by doxofylline plus reduced-dose budesonide (D + RDB) for the second 4-week period. Group B ( n = 30) received D + RDB followed by D + SDB. Clinical outcomes assessed included lung function (forced expiratory volume; in 1 s, FEV1), fractional exhaled nitric oxide (FeNO), asthma control, number of exacerbations and use of rescue medication (salbutamol). Results: It was shown that combined use of doxofylline and ICS may allow children with asthma to reduce their daily dose of ICS while maintaining lung function and improving asthma control ( p = 0.008). There were few asthma exacerbations and only one patient required treatment with systemic corticosteroids. Rescue medication use decreased significantly in patients receiving D + SDB during the first 4-week period. Conclusions: Our results suggest that doxofylline may be a steroid-sparing treatment in asthma, but longer-term, controlled studies are needed to confirm these observations. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|